Lisata Therapeutics to Announce Third Quarter Financial Results
Lisata Therapeutics, Inc. (Nasdaq: LSTA) is excited to announce that it will provide its financial results for the third quarter, which concluded on September 30, 2024. Scheduled for release on November 12, 2024, this report will follow the close of trading. The company, known for its commitment to developing pioneering therapies for serious health conditions, is poised to share significant updates regarding its financial performance.
Conference Call Details
Investors and interested parties are invited to join a conference call that will commence at 4:30 p.m. Eastern time on the day of the report. Registration is required to participate, and attendees are encouraged to sign up ahead of time to ensure timely access to the discussion.
Innovative Approach to Cancer Treatment
Lisata Therapeutics has positioned itself at the forefront of pharmaceutical innovation, particularly in the realm of advanced solid tumors. The company is dedicated to the research and development of new therapies designed to tackle these challenging diseases. One of its promising product candidates is certepetide, an investigational drug that employs a unique mechanism to enhance the efficacy of co-administered or tethered anti-cancer agents, thereby ensuring that treatments more accurately reach cancerous tissues.
About CendR Platform Technology
Lisata's research is underpinned by its proprietary CendR Platform technology, which focuses on improving drug delivery systems for cancer treatment. This innovative approach aims to enhance the targeting and penetration of solid tumors, making cancer therapies more effective. The company is confident that the upcoming clinical trial milestones will not only validate its product candidates but also draw in valuable partnerships.
Looking Ahead: Future Milestones
As Lisata transitions into the next phase of its development, it anticipates substantial achievements that will further highlight its capabilities within the pharmaceutical landscape. The company's strategic vision includes a series of anticipated milestones across various clinical trials over the next 1.5 years. These efforts are aimed at securing continued funding that will support operational activities into early 2026.
Commitment to Stakeholders
Lisata Therapeutics remains committed to transparency with investors and stakeholders. Each financial report will serve as a platform to share progress and insights about their development pipeline. The management team at Lisata believes that continued engagement with stakeholders is crucial in building trust and excitement around their innovative therapies.
Engaging with Lisata Therapeutics
For those wishing to learn more about the exciting developments at Lisata, a live webcast of the upcoming conference call will be available on the company’s website shortly after the conclusion of the call. This accessibility enhances engagement and allows for broader understanding of their progress and plans.
Company Contact Information
For further inquiries, Lisata Therapeutics offers clear communication channels. John Menditto serves as the Vice President of Investor Relations and Corporate Communications and can be reached at 908-842-0084. For media-related questions, Elizabeth Coleman from ICR Healthcare is available at 203-682-4783.
Frequently Asked Questions
What are the key areas of focus for Lisata Therapeutics?
Lisata Therapeutics focuses on developing innovative treatment options for advanced solid tumors and other serious diseases using unique drug delivery mechanisms.
When will Lisata report its third-quarter financial results?
The financial results for the third quarter of 2024 will be reported on November 12, 2024, after the market closes.
How can investors participate in the conference call?
Investors must register for the conference call in advance to participate. They are encouraged to join the call 15 minutes early to avoid any delays.
What is the CendR Platform technology?
The CendR Platform technology is an innovative system that allows for improved targeting and penetration of anti-cancer therapies into solid tumors, enhancing treatment efficacy.
Who are the key contacts for Lisata Therapeutics?
For investor relations, contact John Menditto at 908-842-0084, and for media inquiries, reach out to Elizabeth Coleman at 203-682-4783.
